Does Hemolysis Affect Lactic Acid?

Hemolysis raises measured lactic acid (lactate) levels in blood samples, and the effect is large enough to mislead clinical decisions. Red blood cells are among the body’s most prolific lactate producers because they rely entirely on anaerobic metabolism, so when those cells rupture and spill their contents into the surrounding plasma, the lactate concentration of the sample climbs. The size of the error depends on how severely hemolyzed the specimen is, which analyzer is used, and whether the hemolysis happened inside the patient’s body or in the collection tube. Because lactate is a time-sensitive marker used to guide treatment in sepsis, shock, and other emergencies, understanding this interference is more than an academic concern.

Why Red Blood Cells Matter So Much for Lactate

Red blood cells lack mitochondria. Without the cellular machinery for aerobic metabolism, they generate all of their energy through glycolysis, which produces lactate as an end product. A healthy red blood cell continuously converts glucose to lactate throughout its roughly 120-day lifespan. That means every red blood cell circulating in your blood is, in effect, a tiny lactate factory. When the cell membrane breaks open, the lactate that had been contained inside pours into the plasma or serum surrounding it. A mildly hemolyzed sample might show only a small bump; a grossly hemolyzed one can push lactate readings well above clinically meaningful thresholds.

Research has confirmed that lactate concentrations measured in nonhemolyzed whole blood are simply not comparable with results from hemolyzed whole blood or protein-precipitated whole blood.¹ This finding underscores that the physical state of the red blood cells in your sample directly changes the number the lab reports. It is not a subtle bias that can be ignored at the bedside.

In Vitro Versus In Vivo Hemolysis

Not all hemolysis is created equal. The distinction between hemolysis that happens inside the patient’s body (in vivo) and hemolysis that happens after the blood is drawn (in vitro) matters both for interpreting the lactate result and for deciding what to do about it.

In vitro hemolysis is far more common. It typically stems from problems during blood collection or sample handling: drawing blood through a needle that is too small, using excessive vacuum or turbulence, shaking the tube roughly, or exposing the specimen to temperature extremes. In vivo hemolysis, by contrast, arises from medical conditions that destroy red blood cells within the circulation, including autoimmune hemolytic anemias, transfusion reactions, certain infections, and inherited red blood cell disorders.²

When hemolysis is in vitro, the elevated lactate is purely artifact. The patient’s actual blood lactate may be perfectly normal, and the correct response is to redraw the specimen with better technique. When hemolysis is in vivo, the situation is trickier: the patient’s red blood cells really are being destroyed, which both releases intracellular lactate and reduces the oxygen-carrying capacity of the blood, potentially driving even more lactate production at the tissue level. In that case, a high lactate reading reflects something genuinely going wrong inside the patient, but the measured number still includes an artifactual component from the ruptured cells. Clinicians need to recognize that the “true” tissue-level lactate is likely somewhat lower than what the analyzer reports.

The Hidden Problem with Blood Gas Analyzers

Modern chemistry analyzers used for routine serum and plasma testing can detect hemolysis and flag it. They measure a hemolysis index, a number that reflects how much free hemoglobin is floating in the sample, and when it crosses a threshold the lab can decide to reject the specimen or add a warning to the result. This does not eliminate the problem, but it at least alerts the clinician that something is off.

Blood gas analyzers, however, typically lack this capability. They process whole blood and do not measure or report a hemolysis index.³ This is a practical gap that matters, because lactate is commonly measured on point-of-care blood gas instruments at the bedside, in the emergency department, or in the operating room. A clinician who draws an arterial blood gas, runs it on a bedside analyzer, and sees a lactate of 4.5 mmol/L may assume the number is reliable without realizing that hemolysis during the draw or in the syringe has inflated the value. There is no automatic flag to prompt suspicion.

The implication is straightforward: if a lactate result from a blood gas analyzer seems unexpectedly high and does not match the patient’s clinical picture, consider the possibility of hemolysis. A repeat sample drawn carefully, or a simultaneous venous lactate sent to the central lab on a chemistry analyzer that does measure hemolysis index, can help sort out whether the number is real.

How Much Does Hemolysis Shift the Number?

The magnitude of the error varies depending on the degree of hemolysis and the measurement platform. Mild hemolysis, the kind that produces a faintly pink or salmon-colored sample, might raise lactate by a fraction of a mmol/L. Grossly hemolyzed samples, which appear dark red or nearly opaque, can push lactate readings up by several mmol/L. Because clinical decision thresholds for lactate often sit around 2 mmol/L for concern and 4 mmol/L for aggressive intervention, even a modest artifact can change the category a patient falls into.

The relationship is not perfectly linear, either. Research on hemoglobin-based oxygen carriers, which create a form of free hemoglobin in plasma similar to hemolysis, found that the degree of interference varied across analyzer platforms. On one common chemistry analyzer, a hemoglobin-based product caused lactate to be underestimated by an average of about 0.57 mmol/L, and the underestimation grew worse at higher lactate concentrations.⁴ That study’s context was specific to hemoglobin-based oxygen carriers rather than ordinary hemolysis, but it illustrates an important principle: the direction and size of the interference depend on the analytical method the instrument uses. Some platforms overestimate lactate in hemolyzed samples; others, depending on the chemistry of the assay, may actually underestimate it. The takeaway is that you cannot assume a single predictable direction of error without knowing which analyzer was used.

Sample Handling and Storage Add Another Layer

Hemolysis is not the only pre-analytical variable that can corrupt a lactate result. How a blood sample is handled after collection makes a real difference, and some of these handling issues intersect with hemolysis.

Red blood cells and white blood cells continue to metabolize glucose and produce lactate after blood is drawn. If a sample sits at room temperature without a glycolysis inhibitor like sodium fluoride, lactate will climb steadily, sometimes by enough to double the measured concentration within 30 minutes. This is technically a different problem from hemolysis, but in practice the two often overlap: rough handling that causes hemolysis also tends to accompany delayed processing, and both push lactate in the same direction.

Research on long-term storage shows that samples treated with a combination of an erythrocyte-lysing agent, an anticoagulant, and a glycolysis inhibitor can be stored for up to four weeks without meaningful changes in measured lactate. Beyond that, concentrations start to drift upward: after six weeks of storage, values were on average about 0.8 mmol/L higher than at baseline.⁵ For clinical purposes, lactate samples are analyzed rapidly and this long-term storage issue rarely applies. But for research studies that batch-analyze samples, it is a genuine concern.

Transport systems within hospitals can also introduce hemolysis. Pneumatic tube systems, the pressurized cartridges that whisk specimens from the bedside to the lab through overhead tubes, have long been suspected of causing hemolysis through the mechanical forces of rapid acceleration and abrupt stops. One study at a large hospital found no correlation between pneumatic tube transport and serum hemolysis index, suggesting that well-maintained systems with properly padded carriers do not routinely damage samples.⁶ Still, older or poorly maintained tube systems, or very long transport distances, could pose a higher risk.

Downstream Consequences in the Emergency Department

Hemolysis does not just produce a wrong number on a lab report. It triggers a cascade of practical delays. When a chemistry analyzer flags a specimen as hemolyzed and the lab rejects it, someone has to notify the clinical team, the patient has to be stuck again, and a new sample has to travel back to the lab, be processed, and run. In a time-sensitive clinical scenario where lactate is being used to guide resuscitation, that delay matters.

A study of emergency department blood samples found that hemolysis was independently associated with prolonged patient throughput. Patients whose samples hemolyzed experienced longer times to disposition, regardless of how sick they were or what their triage category was.⁷ The delay is not because the patient is sicker; it is because the lab result is not available. In sepsis, where early lactate-guided therapy can be lifesaving, losing 30 to 60 minutes to a hemolyzed redraw is a real clinical cost.

For this reason, emergency departments and critical care units often train phlebotomy and nursing staff on techniques that minimize hemolysis: using appropriately sized needles, avoiding draws from IV lines when possible, not overfilling or underfilling collection tubes, and mixing anticoagulant tubes gently rather than shaking them. These steps are not just about lab quality for its own sake; they directly affect how quickly the clinical team can act on the result.

What Labs Do When a Hemolyzed Specimen Arrives

Laboratories have developed various approaches for dealing with hemolyzed specimens, though the strategies work better for some analytes than for others. For tests like potassium or lactate dehydrogenase (LDH), where the intracellular concentration in red blood cells is vastly higher than in plasma, even mild hemolysis creates a large artifact, and most labs simply reject the sample and ask for a redraw.

For some analytes, researchers have explored mathematical correction algorithms that adjust the reported value based on the hemolysis index. One study found that for AST and LDH, quantitative corrections could be applied within allowable error margins for mildly hemolyzed specimens when the result was above the upper reference limit, but no reliable correction was possible for results below that limit.⁸ The takeaway is that correction algorithms are analyte-specific and situation-specific; they are not a blanket solution.

For lactate in particular, no widely adopted correction algorithm exists. The relationship between hemolysis severity and lactate artifact is influenced by the patient’s hematocrit, the metabolic state of the red blood cells at the time of collection, and the analytical method, making a one-size-fits-all correction unreliable. The standard practice remains: if the sample is hemolyzed and the lactate is critical for clinical decisions, redraw and retest.

Sickle Cell Disease and Other Hemolytic Conditions

Patients with chronic hemolytic conditions present a special challenge for lactate interpretation. In sickle cell disease, for example, red blood cells have a shortened lifespan and undergo ongoing destruction. This chronic in vivo hemolysis contributes to a baseline elevation of resting lactate levels. Research has found that individuals with sickle cell disease, regardless of whether their liver or kidneys are involved, show a metabolic shift from aerobic to anaerobic pathways, likely driven by the reduced oxygen delivery that results from sickling and the lower total number of functional red blood cells.⁹

This means a lactate of 2.5 mmol/L in a patient with sickle cell disease does not necessarily mean the same thing as a lactate of 2.5 mmol/L in someone without a hemolytic disorder. Part of that elevation may be the patient’s new normal, reflecting chronic tissue hypoxia and ongoing red cell destruction rather than an acute crisis. Clinicians who care for these patients learn to establish a baseline lactate during stable periods and to focus on the trend, how much the lactate has risen from the patient’s own baseline, rather than comparing it to population-level cutoffs.

Similar reasoning applies to other chronic hemolytic conditions, such as hereditary spherocytosis, thalassemia major with ongoing hemolysis, and patients with mechanical heart valves that cause low-grade red cell shearing. In each case, the chronic destruction of red blood cells creates a steady-state contribution to the circulating lactate pool that makes standard thresholds less useful.

Practical Steps to Get a Reliable Lactate

Minimizing hemolysis starts at the moment the needle enters the vein. Drawing blood through an appropriately sized needle, avoiding excessive tourniquet time, and steering clear of draws from existing IV catheters (where turbulence and flush solutions can lyse cells) all reduce the odds of artifact. Once collected, the sample should be transported smoothly, kept at a stable temperature, and analyzed promptly. For whole blood samples, placing them on ice slows ongoing glycolysis, though freezing and thawing introduces its own hemolysis risk.

If you work in a clinical setting and receive a lactate result that does not match the patient, check the hemolysis index if it is available. On a blood gas analyzer where no index is reported, look at the sample visually: pink or red-tinged plasma in a spun specimen suggests hemolysis. When in doubt, a carefully drawn repeat sample is the most reliable way to confirm whether the number is real.

Point-of-care lactate devices used in prehospital settings and resource-limited environments face similar vulnerabilities. The small sample volumes, capillary blood draws, and exposure to ambient conditions all create opportunities for hemolysis and glycolytic artifact. Operators of these devices should follow manufacturer guidance on sample type and handling, and should treat unexpectedly high readings with the same skepticism they would apply to any lab result that clashes with the clinical picture.

When Hemolysis and Lactate Collide in Research

The hemolysis-lactate interaction matters beyond the bedside. In exercise science, sports medicine, and veterinary research, lactate is commonly measured in field settings where sample handling is less controlled than in a hospital lab. Fingertip capillary samples collected at the finish line of a race, for example, are especially vulnerable to hemolysis from squeezing the finger, exposure to sweat, and delays before analysis. Researchers who study lactate thresholds or use lactate curves to guide training need to account for these pre-analytical variables, or risk building training protocols on numbers that are partly artifact.

The finding that properly treated blood samples can be stored for up to four weeks without meaningful lactate drift is reassuring for researchers who need to batch-process specimens.⁵ But the key word is “properly treated.” Without a glycolysis inhibitor, samples left at room temperature will show rising lactate within minutes. And without an erythrocyte-lysing agent added intentionally and consistently, the degree of accidental hemolysis will vary from sample to sample, introducing random noise that can obscure real physiological differences between study conditions.

Veterinary medicine faces its own version of this challenge. Red blood cell fragility varies across species, meaning the ease with which cells hemolyze during routine blood draws is not the same in a dog, a horse, or a cat. Lactate is increasingly used in emergency veterinary medicine to assess prognosis in conditions like gastric dilatation-volvulus in dogs or colic in horses, and the same caution about hemolysis applies. Hemolyzed samples in veterinary patients should prompt the same question they do in human medicine: is this number real, or is it partly artifact?